These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 25891010

  • 1. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [Abstract] [Full Text] [Related]

  • 2. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [Abstract] [Full Text] [Related]

  • 3. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, Antón J, Wang Z, Meszaros G, Araújo J, Liao R, Keller S, Brunner HI, Ruperto N, JUVE-BASIS investigators, Paediatric Rheumatology International Trials Organisation.
    Lancet; 2023 Aug 12; 402(10401):555-570. PubMed ID: 37423231
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
    Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2014 Jun 12; 73(6):1114-22. PubMed ID: 23696632
    [Abstract] [Full Text] [Related]

  • 5. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M.
    J Formos Med Assoc; 2004 Aug 12; 103(8):618-23. PubMed ID: 15340661
    [Abstract] [Full Text] [Related]

  • 6. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization, Pediatric Rheumatology Collaborative Study Group.
    Lancet; 2008 Aug 02; 372(9636):383-91. PubMed ID: 18632147
    [Abstract] [Full Text] [Related]

  • 7. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I, Constantin T, Vojinović J, Horneff G, Chasnyk V, Dehoorne J, Panaviene V, Sušić G, Stanevicha V, Kobusinska K, Zuber Z, Dobrzyniecka B, Nikishina I, Bader-Meunier B, Breda L, Doležalová P, Job-Deslandre C, Rumba-Rozenfelde I, Wulffraat N, Pedersen RD, Bukowski JF, Vlahos B, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO).
    Arthritis Res Ther; 2019 May 23; 21(1):125. PubMed ID: 31122296
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2010 Jun 23; 62(6):1792-802. PubMed ID: 20191582
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May 23; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J, Cooper K, Harris P, Picot J, Rose M.
    Health Technol Assess; 2016 Apr 23; 20(34):1-222. PubMed ID: 27135404
    [Abstract] [Full Text] [Related]

  • 14. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR, Keating GM.
    Drugs; 2002 Apr 23; 62(17):2493-537. PubMed ID: 12421111
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 17. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.
    Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, Cate RT, Koopman-Keemink Y, van Santen-Hoeufft M, Raat H, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2010 Jan 07; 69(1):138-42. PubMed ID: 19581280
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.
    Arthritis Care Res (Hoboken); 2014 Feb 07; 66(2):253-62. PubMed ID: 23983081
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.
    Mod Rheumatol; 2012 Sep 07; 22(5):720-6. PubMed ID: 22212889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.